The use of interferon alpha in multiple myeloma;UTILISATION DE L'INTERFERON ALPHA DANS LE MYELOME MULTIPLE

Revue de Medecine Interne

Volumn 17, Issue 6, 1996, Pages 488-495

  Harousseau, J L ^a   Klein, B ^b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Hôpital Saint ÉIoi   (France)

Author keywords

interferon alpha; multiple myeloma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; MULTICENTER STUDY; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INTERFERON-ALPHA; MULTIPLE MYELOMA;

EID: 0029952360     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)86444-7     Document Type: Article

References (53)

1. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon alpha produces subtained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991;114:532-8
2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-5
3. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995;122:254-61
4. Quesada JR, Alexanian R, Hawkins M et al. Treatment of multiple myeloma with alpha interferon. Blood 1986;67:275-81
5. Golomb H, Ellis E. Treatment options for hairy-cell leukemia. Semin Oncol 1991;18(suppl 7):7-11
6. Rozman C, Montserrat E, Vinolas N et al. Recombinant A2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 1988;71:1295-8
7. Smalley RV, Andersen JW, Hawkins MJ et al. Interferon alpha combined with cytotoxic chemotherapy for patients witn nonhodgkin's lymphoma. N Engl J Med 1992;327:1336-41
8. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant-Interferon alpha-2b combined with a regimen containing Doxorubicin in patients with advanced follicular lymphoma. Groupe d'étude des lymphomes de l'adulte. N Engl J Med 1993;329:1608-14
9. Cooper MR. Interferon in the management of multiple myeloma. Semm Oncol 1988;15:21-5
10. Mellstedt H, Ahre A, Bjorkholm M et al. Interferon therapy in myelomatosis. Lancet 1979;i:245-7
11. Alexanian R, Gutterman J, Levy H. Interferon treatment for multiple myeloma. Clin Hematol 1982;11:211-20
12. Mellstedt H, Ahre A, Bjorkholm M et al. Interferon therapy of patients with myeloma. In: Rosenberg T, ed. Immunotherapy of human cancer. Amsterdam: Elsevier North Holland, 1982;387-91
13. Ahre A, Bjorkholm M, Mellstedt H et al. Human leucocyte interferon and intermittent high-dose melphalan/prednisone administration in the treatment of multiple myeloma. A randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984;68:1331-7
14. Ludwig H, Cortelezzi A, Scheithauer W et al. Recombinant interferon alpha 2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986;22:1111-7
15. Quesada JR, Alexanian R, Halukins M et al. Treatment of multiple myeloma with alpha interferon. Blood 1986;67:275-81
16. Ohno R. Interferon in the treatment of multiple myeloma. Int J Cancer 1987;suppl1:14-8
17. Mandelli F, Avvisati G, Amadori S et al. Maintenance therapy with recombinant interferon 2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-4
18. Avvisati G, Boccadoro M, Petrucci MT et al. Interferon alpha as maintenance treatment in multiple myeloma: the Italian Experience. Proceeding IVth International. Workshop on Multiple Myeloma, Rochester, 87-88, 2-5 October 1993
19. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2405-14
20. Westin J, Rödjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995;89:561-8
21. Browman G, Bergsagel DE, Sichert D et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 1995;13:2354-60
22. Peest D, Deicher H, Coldewey R et al. A comparison of polychemotherapy and Melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Europ J Cancer 1995;89:328-37
23. Ludwig H, Cohen AM, Polliack A et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of others studies. Ann Oncol 1995;6:467-6
24. Blade J. San Miguel JF, Escudero ML, Fontanilles M. Maintenance treatment with interferon alpha-2b in multiple myeloma. Proceedings of the Vth International Workshop on Multiple Myeloma, La Baule, 1995:394-5
25. Jourdan M, Zhang XG, Portier M et al. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991;147:4402-7
26. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72
27. Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukemia under interferon alpha therapy. Br J Haematol 1991;79:523-5
28. Sawamura M, Murayama K, Vi G et al. Plasma cell leukemia with alpha interferon therapy in myeloma [letter], Br J Haematol 1992;82:631
29. Grander D, Von Stedingk LV, Von Stedingk M et al. Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma. Eur J Haematol 1991;46:17-22
30. Tanaka M, Tanabe O, Iwato K et al. Sensitive inhibitory effect of interferon alpha on M protein secretion of human myeloma cells, Blood 1989;74:1718-22
31. Palumbo A, Battaglio S, Napoli P et al. Recombinant interferon-γ inhibits the in vitro proliferation of human myeloma cells. Br J Haematol 1994;86:726-32
32. Brenning G. The in vitro effect of leucocyte alpha interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985;35:178-85
33. Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand J Haematol 1985;35:543-9
34. Attal M, Huguet F, Schlaifer D et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992;79:1130-6
35. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the french registry on autologous transplantation in multiple myeloma. Blood 1995;11:3077-85
36. Cunningham D, Powles R, Viner C et al. High dose chemotherapy and autologous bone marrow transplantation in multiple myeloma. Proceedings of the IVth International Workshop on Multiple Myeloma, Rochester, 2-5 October 1993, 102
37. Aapro MS, Alberts DS, Salmon SE. Interactions of human leucocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983;10:161-6
38. Balkwill FR, Moodey EM. Positive interactions between interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1985;44:906-8
39. Welander CE, Morgan TM, Homesley HD et al. Combined recombinant human Interferon alpha 2 and cytotoxic agents studied in the clonogenic assay. Int J Cancer 1985;35:721-9
40. Oken MM, Kyle RA, Greipp PR et al. Complete remission induction with VBMCP + interferon (rIFN alpha2) in multiple myeloma: 3 years follow up. Proc Am Soc Clin Oncol 1989;8:272
41. Oken MM, Leong T, Kay NE et al. The effect of adding interferon or high-dose cyclophosphamide to VBMCP to treat multiple myeloma results of an ECOG phase III trial [Abstract]. Blood 1995;86(suppl 1):441a
42. Osterborg A, Bjorkholm M, Bjoneman M et al. Natural interferon alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993;81:1428-34
43. Cooper MR, Dear K, McIntyre OR et al. A randomized clinical trial comparing Melphalan/Prednisone with or without Interferon alpha-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B Study. J Clin Oncol 1993;11:155-60
44. Corrado C, Pavlovsky S, Saslasky J et al. Randomized trial comparing Melphalan/Prednisone with or without recombinant alpha 2 interferon in multiple myeloma. Proc Am Soc Clin Oncol 1989;8:1007
45. Montuoro A, De Rosa L, De Blasio A et al. Alpha 2 Interferon/melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990:76;365-8
46. Casassus P, Pegourie-Bandelier B, Sadouna A et al. Randomized comparison of interferon with VMCPWBAP as the induction phase of untreated multiple myeloma: results of the KIF multicentric trial [Abstract]. Blood 1995;86(suppl 1):441a
47. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refrectory to alkylating agents. N Engl J Med 1984;310:1353-6
48. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90
49. Dimopoulos MA, Weber D, Delasalle KB et al. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer 1993;72:2589-95
50. Lichtenstein A, Tu YP, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Imunol 1995;162:248-55
51. Zhang XG, Gu ZJ, Lu ZY et al. Ciliary neurotropic factor, interleukin 11, leukemia inbitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gpl30. J Exp Med 1994;179:1337-42
52. Lu ZY, Zhang XG, Wijdenes J et al. Interleukin 10 is a growth factor for human myeloma cells. Blood 1995;85:2521-7
53. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin 6 family of cytokines and gp 130. Blood 1995;86:1234-54